NCT02453061View on ClinicalTrials.gov

A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

June 29, 2015

Primary Completion Date

December 3, 2019

Study Completion Date

December 3, 2019

Conditions

Huntington Disease

Interventions

DRUG

Triheptanoin oil

Triheptanoin oil orally administered at 1g/kg/day

DRUG

Placebo

Safflower oil orally administered at 1g/kg/day

Trial Locations (2)

75013

Département de Génétique, Paris

2300RC

Department of Neurology, Leiden

All Listed Sponsors

collaborator

Ultragenyx Pharmaceutical Inc

INDUSTRY

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT02453061 - A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease | Biotech Hunter | Biotech Hunter